A Phase 1 interventional study of saxagliptin and metformin XR in Diabetes Mellitus, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-21.
Sponsored by AstraZeneca · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing saxagliptin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. saxagliptin · Diabetes Mellitus.
Among the 10 studies testing saxagliptin in Diabetes Mellitus, this one is the 8th largest by enrollment, is one of 2 that started in 2009, is one of 3 in phase 1, and was the 4th registered.
8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →None of the 10 studies testing saxagliptin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →
saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 66 across the 10 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 4 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
122 studies in Diabetes Mellitus by AstraZeneca: none open now, none under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 122 studies in Diabetes Mellitus by AstraZeneca, this one is the 74th largest by enrollment of the 91 interventional ones that give a count, is one of 13 that started in 2009, is one of 20 in phase 1, and was the 83rd registered.
AstraZeneca’s Diabetes Mellitus studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing saxagliptin in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 122 in Diabetes Mellitus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate bioequivalence (BE) of a 5 mg saxagliptin/500 mg metformin extended release (XR) fixed-dose combination (FDC) tablet (manufactured in Mt Vernon, Indiana [IN]) to coadministered 5 mg saxagliptin and 500 mg metformin XR tablet (manufactured in Evansville, IN) in fed healthy subjects.
This study is designed to evaluate if the FDC tablet of 5 mg saxagliptin/500 mg metformin extended release (manufactured in Mt Vernon, Indiana) is bioequivalent to the coadministered 5 mg saxagliptin and 500 mg metformin XR tablet (manufactured in Evansville, Indiana)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: saxagliptin · Drug: metformin XR
under fed state
Drug: saxagliptin + metformin XR (FDC tablet)
under fasted state
Drug: saxagliptin + metformin XR (FDC tablet)
Tablets, Oral, 5 mg, once daily, Single dose
Also known as: Onglyza
Tablets, Oral, 500 mg. once daily, Single dose
Also known as: Glucophage XR
Drug pages: Saxagliptin · Metformin
Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose
Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])
Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \[calculated using the linear trapezoidal rule\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant
Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Saxagliptin Observed Maximum Plasma Concentration (Cmax)
Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Metformin AUC(0-inf)
Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \[calculated using the linear trapezoidal rule\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant
Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Metformin Cmax
Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Saxagliptin Terminal Half-life (T1/2)
terminal half life; calculated as ln(2)/Kel
Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])
Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.
Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Time to Achieve the Observed Maximum Saxagliptin Plasma Concentration (Tmax)
Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Saxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf])
Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Active Metabolite BMS-510849 AUC(0-inf)
Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \[calculated using the linear trapezoidal rule\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant
Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Active Metabolite BMS-510849 AUC(0-t)
Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.
Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Active Metabolite BMS-510849 Cmax
Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Active Metabolite BMS-510849 T1/2
terminal half life; calculated as ln(2)/Kel
Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Active Metabolite BMS-510849 Tmax
Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Active Metabolite BMS-510849 AUC(0-t)/AUC(0-inf)
Time frame: Period 1 (samples taken before dosing, and at 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)
Metformin AUC(0-t)
Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.
Time frame: Period 1 (samples taken before dosing, and at 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)
Metformin T1/2
terminal half life; calculated as ln(2)/Kel
Time frame: Period 1 (before dosing, 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)
Metformin Tmax
Time frame: Periods 1, 2, and 3 (before dosing, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Metformin Fraction of AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf])
Time frame: Period 1 (before dosing, 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)
Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
Time frame: AEs: from initiation of study drug administration on Day 1/Period 1 through study discharge Day 3/Period 3. SAEs: from date of written consent until 30 days after discontinuation of dosing or participation in study if last scheduled visit occurred later.
Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and Electrocardiogram (ECG) Abnormalities
Abnormalities considered by the investigator to be clinically significant and/or reported as an AE.
Time frame: From Day 1 of Period 1 through Day 3 of Period 3 (study discharge)
| Milestone | Treatment Sequence ABC | Treatment Sequence ACB | Treatment Sequence BAC | Treatment Sequence BCA | Treatment Sequence CAB | Treatment Sequence CBA |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence ABC | Treatment Sequence ACB | Treatment Sequence BAC | Treatment Sequence BCA | Treatment Sequence CAB | Treatment Sequence CBA |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence ABC | Treatment Sequence ACB | Treatment Sequence BAC | Treatment Sequence BCA | Treatment Sequence CAB | Treatment Sequence CBA |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \[calculated using the linear trapezoidal rule\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant
| ng*hr/mL | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf]) | 107.28 ± 25.13 | 111.72 ± 26.55 | 103.35 ± 23.15 |
terminal half life; calculated as ln(2)/Kel
| hours | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Saxagliptin Terminal Half-life (T1/2) | 8.46 ± 2.85 | 8.56 ± 3.04 | 9.21 ± 3.91 |
Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.
| ng*hr/mL | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t]) | 105.47 ± 24.98 | 109.88 ± 26.36 | 101.52 ± 23.01 |
| ng/mL | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Saxagliptin Observed Maximum Plasma Concentration (Cmax) | 26.84 ± 8.26 | 27.25 ± 7.95 | 28.85 ± 8.62 |
| hours | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Time to Achieve the Observed Maximum Saxagliptin Plasma Concentration (Tmax) | 1.65 ± 0.65 | 1.48 ± 0.75 | 0.65 ± 0.50 |
| ratio | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Saxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf]) | 0.983 ± 0.006 | 0.983 ± 0.006 | 0.982 ± 0.008 |
Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \[calculated using the linear trapezoidal rule\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant
| ng*hr/mL | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Active Metabolite BMS-510849 AUC(0-inf) | 291.72 ± 79.21 | 295.94 ± 75.40 | 289.06 ± 66.89 |
Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.
| ng*hr/mL | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Active Metabolite BMS-510849 AUC(0-t) | 284.46 ± 78.25 | 289.03 ± 74.80 | 281.79 ± 65.91 |
| ng/mL | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Active Metabolite BMS-510849 Cmax | 49.71 ± 16.94 | 49.28 ± 14.59 | 49.09 ± 15.46 |
terminal half life; calculated as ln(2)/Kel
| hours | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Active Metabolite BMS-510849 T1/2 | 13.88 ± 1.53 | 13.65 ± 1.72 | 14.04 ± 1.33 |
| hours | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Active Metabolite BMS-510849 Tmax | 2.38 ± 0.76 | 2.42 ± 0.88 | 1.46 ± 0.70 |
| ratio | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Active Metabolite BMS-510849 AUC(0-t)/AUC(0-inf) | 0.974 ± 0.008 | 0.975 ± 0.008 | 0.974 ± 0.006 |
Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \[calculated using the linear trapezoidal rule\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant
| ng*hr/mL | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Metformin AUC(0-inf) | 5865.92 ± 2357.15 | 5516.97 ± 2423.08 | 5073.70 ± 1406.45 |
Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.
| ng*hr/mL | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Metformin AUC(0-t) | 5617.39 ± 2181.99 | 5200.46 ± 2203.34 | 4896.95 ± 1340.41 |
| ng/mL | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Metformin Cmax | 629.73 ± 160.14 | 586.87 ± 150.63 | 657.23 ± 187.67 |
terminal half life; calculated as ln(2)/Kel
| hours | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Metformin T1/2 | 10.7 ± 5.90 | 12.6 ± 7.05 | 14.9 ± 7.40 |
| hours | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Metformin Tmax | 4.78 ± 1.04 | 4.90 ± 1.13 | 4.11 ± 0.88 |
| ratio | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Metformin Fraction of AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf]) | 0.979 ± 0.020 | 0.970 ± 0.026 | 0.965 ± 0.031 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
| Participants | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Number of Participants With At Least 1 AE | 3 | 2 | 4 |
| Discontinuation Due to an AE | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 |
| SAEs | 0 | 0 | 0 |
Abnormalities considered by the investigator to be clinically significant and/or reported as an AE.
| Participants | Treatment A - Saxagliptin + Metformin XR, Fed | Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed | Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting |
|---|---|---|---|
| Clinical Laboratory Abnormalities | 0 | 0 | 0 |
| Vital Sign Abnormalities | 0 | 0 | 0 |
| Physical Examination Abnormalities | 0 | 0 | 0 |
| 12-Lead ECG Abnormalities | 0 | 0 | 0 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | — | 0/30 (0%) | 3/30 (10%) |
| Treatment C | — | 0/30 (0%) | 4/30 (13.3%) |
| Treatment B | — | 0/30 (0%) | 2/30 (6.7%) |
| Event | Treatment A | Treatment C | Treatment B |
|---|---|---|---|
| HEADACHENervous system disorders | 0/30 | 1/30 | 1/30 |
| PRESYNCOPENervous system disorders | 0/30 | 1/30 | 0/30 |
| NAUSEAGastrointestinal disorders | 0/30 | 1/30 | 0/30 |
| DIARRHOEAGastrointestinal disorders | 0/30 | 1/30 | 1/30 |
| DRY MOUTHGastrointestinal disorders | 0/30 | 1/30 | 0/30 |
| FLATULENCEGastrointestinal disorders | 0/30 | 0/30 | 1/30 |
| CHAPPED LIPSGastrointestinal disorders | 0/30 | 1/30 | 0/30 |
| CONSTIPATIONGastrointestinal disorders | 0/30 | 0/30 | 1/30 |
| LIP SWELLINGGastrointestinal disorders | 1/30 | 0/30 | 0/30 |
| ABDOMINAL DISTENSIONGastrointestinal disorders | 0/30 | 0/30 | 1/30 |
| Age, Continuous(years) | All Enrolled and Treated Participants |
|---|---|
| Mean | 29.1 ± 8.0 |
| Sex: Female, Male(Participants) | All Enrolled and Treated Participants |
|---|---|
| Female | 14 |
| Male | 16 |
| Race/Ethnicity, Customized(participants) | All Enrolled and Treated Participants |
|---|---|
| White | 17 |
| Black or African American | 12 |
| Asian | 1 |
| Race/Ethnicity, Customized(participants) | All Enrolled and Treated Participants |
|---|---|
| Hispanic or Latino | 9 |
| Not Hispanic or Latino | 21 |
| Height(cm) | All Enrolled and Treated Participants |
|---|---|
| Mean | 170.0 ± 9.22 |
| Weight(kg) | All Enrolled and Treated Participants |
|---|---|
| Mean | 78.31 ± 13.74 |
| Body Mass Index(kg/m^2) | All Enrolled and Treated Participants |
|---|---|
| Mean | 26.97 ± 3.07 |
The record gives a start of Nov 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Saxagliptin · Metformin